Transcriptional profiling of matched patient biopsies clarifies molecular determinants of enzalutamide-induced lineage plasticity.
Journal Article (Journal Article)
The androgen receptor (AR) signaling inhibitor enzalutamide (enza) is one of the principal treatments for metastatic castration-resistant prostate cancer (CRPC). Several emergent enza clinical resistance mechanisms have been described, including lineage plasticity in which the tumors manifest reduced dependency on the AR. To improve our understanding of enza resistance, herein we analyze the transcriptomes of matched biopsies from men with metastatic CRPC obtained prior to treatment and at progression (n = 21). RNA-sequencing analysis demonstrates that enza does not induce marked, sustained changes in the tumor transcriptome in most patients. However, three patients' progression biopsies show evidence of lineage plasticity. The transcription factor E2F1 and pathways linked to tumor stemness are highly activated in baseline biopsies from patients whose tumors undergo lineage plasticity. We find a gene signature enriched in these baseline biopsies that is strongly associated with poor survival in independent patient cohorts and with risk of castration-induced lineage plasticity in patient-derived xenograft models, suggesting that tumors harboring this gene expression program may be at particular risk for resistance mediated by lineage plasticity and poor outcomes.
- Westbrook, TC; Guan, X; Rodansky, E; Flores, D; Liu, CJ; Udager, AM; Patel, RA; Haffner, MC; Hu, Y-M; Sun, D; Beer, TM; Foye, A; Aggarwal, R; Quigley, DA; Youngren, JF; Ryan, CJ; Gleave, M; Wang, Y; Huang, J; Coleman, I; Morrissey, C; Nelson, PS; Evans, CP; Lara, P; Reiter, RE; Witte, O; Rettig, M; Wong, CK; Weinstein, AS; Uzunangelov, V; Stuart, JM; Thomas, GV; Feng, FY; Small, EJ; Yates, JA; Xia, Z; Alumkal, JJ
- September 15, 2022
Volume / Issue
- 13 / 1
Start / End Page
- 5345 -
Pubmed Central ID
Electronic International Standard Serial Number (EISSN)
Digital Object Identifier (DOI)